Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) saw a significant drop in short interest in January. As of January 15th, there was short interest totalling 47,300 shares, a drop of 23.1% from the December 31st total of 61,500 shares. Based on an average trading volume of 122,300 shares, the short-interest ratio is presently 0.4 days.

Entera Bio Stock Performance

NASDAQ ENTX opened at $2.38 on Thursday. Entera Bio has a one year low of $0.68 and a one year high of $3.35. The stock has a 50-day moving average of $2.16 and a 200 day moving average of $1.91. The company has a market capitalization of $85.17 million, a price-to-earnings ratio of -9.15 and a beta of 1.49.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Entera Bio in a research report on Monday, November 11th.

Institutional Trading of Entera Bio

Large investors have recently made changes to their positions in the stock. Parkman Healthcare Partners LLC lifted its position in Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after purchasing an additional 9,558 shares during the period. Perigon Wealth Management LLC bought a new position in shares of Entera Bio during the 4th quarter valued at $325,000. Finally, Signature Estate & Investment Advisors LLC purchased a new position in shares of Entera Bio in the 3rd quarter worth $90,000. 14.11% of the stock is currently owned by institutional investors.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.